As the probiotic segment continues to trend upward, more companies are investing in well-designed clinical trials to support efficacy.
One area that has presented substantial learning opportunities, and has helped shape the future of probiotic clinical trials, is the study of antibiotic associated diarrhea (AAD) and probiotic intake.
In a new guest post for the International Probiotic Association (IPA), Josh Baisley, Associate Director of Clinical Trials at Nutrasource, discusses key learning points in this emerging field of study. These include guidance on how to:
- Understand potential confounding factors that could compromise a trial
- Define, measure and analyze appropriate study endpoints
- Choose an appropriate population for the health indication
- Better interpret and use a study's results
Josh Baisley, B.Sc., is Director of Domestic Clinical Trials at Nutrasource. With nearly 15 years of experience in quality assurance, clinical, pre-clinical, and regulatory affairs for the natural health products sector, Josh has been directly involved in over 65 clinical trials accounting for more than 10% of all clinical research applications received by Health Canada. Connect with Josh on LinkedIn.